[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novabridge Biosciences ADR (NBP)

Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,107
  • Shares Outstanding, K 115,649
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,270 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.88

Options Overview Details

View History
  • Implied Volatility 0.00% (-313.35%)
  • Historical Volatility 48.55%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,254.89% on 02/13/26
  • IV Low 0.00% on 05/27/26
  • Expected Move (DTE 21) 0.7140 (38.18%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 97
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,326
  • Open Int (30-Day) 828
  • Expected Range 1.1560 to 2.5840

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 1
  • High Estimate $-0.12
  • Low Estimate $-0.12
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6700 +11.98%
on 05/19/26
2.6700 -29.96%
on 04/29/26
-0.5600 (-23.05%)
since 04/27/26
3-Month
1.6700 +11.98%
on 05/19/26
3.8600 -51.55%
on 03/05/26
-1.4100 (-42.99%)
since 02/27/26
52-Week
1.0600 +76.42%
on 05/28/25
6.7900 -72.46%
on 10/16/25
+0.8300 (+79.81%)
since 05/27/25

Most Recent Stories

More News
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.8700 (+0.54%)
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial...

NBP : 1.8700 (+0.54%)
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data Givastomig, a potential...

NBP : 1.8700 (+0.54%)
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response...

NBP : 1.8700 (+0.54%)
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment...

NBP : 1.8700 (+0.54%)
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD,...

NBP : 1.8700 (+0.54%)
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.8700 (+0.54%)
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around...

NBP : 1.8700 (+0.54%)
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line...

NBP : 1.8700 (+0.54%)
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.8700 (+0.54%)

Business Summary

NovaBridge Biosciences is a biotechnology platform company committed to accelerating access to innovative medicines. NovaBridge Biosciences, formerly known as I-MAB, is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 2.0233
2nd Resistance Point 1.9767
1st Resistance Point 1.9233
Last Price 1.8700
1st Support Level 1.8233
2nd Support Level 1.7767
3rd Support Level 1.7233

See More

52-Week High 6.7900
Fibonacci 61.8% 4.6011
Fibonacci 50% 3.9250
Fibonacci 38.2% 3.2489
Last Price 1.8700
52-Week Low 1.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.